231 related articles for article (PubMed ID: 29499421)
1. Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy.
Verhoeven D; Stoppelenburg AJ; Meyer-Wentrup F; Boes M
Clin Immunol; 2018 May; 190():22-31. PubMed ID: 29499421
[TBL] [Abstract][Full Text] [Related]
2. Effect of haematological malignancies and their treatment on host defence factors.
Hersh EV; Gutterman JU; Mavligit GM
Clin Haematol; 1976 Jun; 5(2):425-48. PubMed ID: 780032
[TBL] [Abstract][Full Text] [Related]
3. Hematological Malignancies Associated With Primary Immunodeficiency Disorders.
Duan L; Grunebaum E
Clin Immunol; 2018 Sep; 194():46-59. PubMed ID: 29966714
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.
Nagorsen D; Bargou R; Ruttinger D; Kufer P; Baeuerle PA; Zugmaier G
Leuk Lymphoma; 2009 Jun; 50(6):886-91. PubMed ID: 19455460
[TBL] [Abstract][Full Text] [Related]
5. Targeting malignant B cells of lymphoma and leukemia with genetically engineered T-cell clones.
Jensen MC
Cytotherapy; 2002; 4(5):443-4. PubMed ID: 12473219
[No Abstract] [Full Text] [Related]
6. Immune checkpoint blockade in lymphoid malignancies.
Thanarajasingam G; Thanarajasingam U; Ansell SM
FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
[TBL] [Abstract][Full Text] [Related]
7. T cell modulation in immunotherapy for hematological malignancies.
Lin C; Chen S; Li Y
Cell Biol Toxicol; 2017 Aug; 33(4):323-327. PubMed ID: 28474249
[No Abstract] [Full Text] [Related]
8. How immunology is reshaping clinical disciplines: the example of haematology.
Caligaris-Cappio F
Lancet; 2001 Jul; 358(9275):49-55. PubMed ID: 11454399
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal antibodies for lymphomas and leukemias in 2005].
Peffault de Latour R; Robin M; Bay JO
Bull Cancer; 2006 Jan; 93(1):107-18. PubMed ID: 16455513
[TBL] [Abstract][Full Text] [Related]
10. Born to survive: how cancer cells resist CAR T cell therapy.
Lemoine J; Ruella M; Houot R
J Hematol Oncol; 2021 Nov; 14(1):199. PubMed ID: 34809678
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Immune Tolerance in Leukemia and Lymphoma.
Curran EK; Godfrey J; Kline J
Trends Immunol; 2017 Jul; 38(7):513-525. PubMed ID: 28511816
[TBL] [Abstract][Full Text] [Related]
12. Immune Therapy of Lympho-Hemopoietic Malignancies.
Echchannaoui H; Theobald M
Oncol Res Treat; 2017; 40(11):652-653. PubMed ID: 29065397
[No Abstract] [Full Text] [Related]
13. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Rezaei N; Hedayat M; Aghamohammadi A; Nichols KE
J Allergy Clin Immunol; 2011 Jun; 127(6):1329-41.e2; quiz 1342-3. PubMed ID: 21514636
[TBL] [Abstract][Full Text] [Related]
14. Genetic predisposition and hematopoietic malignancies in children: Primary immunodeficiency.
van der Werff Ten Bosch J; van den Akker M
Eur J Med Genet; 2016 Dec; 59(12):647-653. PubMed ID: 26975585
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T lymphocytes for leukemia and lymphoma.
Bollard CM; Barrett AJ
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):565-9. PubMed ID: 25696912
[TBL] [Abstract][Full Text] [Related]
16. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.
Waldmann TA
Oncogene; 2007 May; 26(25):3699-703. PubMed ID: 17530023
[TBL] [Abstract][Full Text] [Related]
17. The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective.
Baron F; Storb R
Best Pract Res Clin Haematol; 2006; 19(4):637-53. PubMed ID: 16997174
[TBL] [Abstract][Full Text] [Related]
18. New approaches in the immunotherapy of haematological malignancies.
Costello RT; Rey J; Fauriat C; Gastaut JA; Olive D
Eur J Haematol; 2003 May; 70(5):333-45. PubMed ID: 12694173
[TBL] [Abstract][Full Text] [Related]
19. Advances in immunotherapy of hematologic malignancies.
Maloney DG
Curr Opin Hematol; 1998 Jul; 5(4):237-43. PubMed ID: 9747629
[TBL] [Abstract][Full Text] [Related]
20. Programming the immune checkpoint to treat hematologic malignancies.
Vick E; Mahadevan D
Expert Opin Investig Drugs; 2016 Jul; 25(7):755-70. PubMed ID: 27070269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
